In adult patients with autoimmune encephalitis, when is rituximab indicated, what dosing schedule is recommended, and what monitoring should be performed?

Rituximab for Autoimmune Encephalitis

Rituximab should be initiated as second-line therapy when patients fail to show meaningful clinical or radiological improvement after 2-4 weeks of optimized first-line immunotherapy (corticosteroids, IVIG, or plasmapheresis), with the standard dosing being either 375 mg/m² weekly for 4 weeks or 1000 mg given twice, 2 weeks apart. 1

When Rituximab is Indicated

Second-Line Therapy Criteria

• Primary indication: No meaningful response to first-line therapy (corticosteroids, IVIG, or plasmapheresis) after 2-4 weeks 1
• Preferred over cyclophosphamide in 80% of clinical scenarios when antibody status is unknown, due to superior safety profile 1
• Particularly effective for antibody-mediated autoimmune encephalitis, especially:
  • Anti-NMDAR encephalitis
  • Faciobrachial dystonic seizures (LGI1-antibody)
  • Other neuronal surface antibody syndromes 1

Clinical Decision Points

Earlier initiation may be considered (before completing 2-4 weeks of first-line therapy) in:

• Severe initial presentations (severe NMDAR encephalitis, new-onset refractory status epilepticus, severe dysautonomia)
• Known antibody-mediated disease with typical presentations
• Patients deteriorating despite first-line therapy 1

Important caveat: While rituximab primarily targets B-cells, it may be less effective for cell-mediated inflammation (antibodies against intracellular antigens). However, it indirectly suppresses T-cell activity by reducing B-cell drive to T-cells, making it reasonable even when antibody results are pending 1

Dosing Schedules

Standard Acute Treatment Regimens

Two equally acceptable options 1:

1. Lymphoma protocol: 375 mg/m² IV weekly for 4 consecutive weeks
2. Rheumatology protocol: 1000 mg IV on day 1 and day 15 (two doses, 2 weeks apart)

Emerging Evidence for Lower Doses

Recent research suggests 100 mg weekly for 3 weeks, followed by 100 mg every 6 months may be effective with potentially fewer side effects, though this is not yet standard practice 2

Maintenance/Relapse Prevention

• For relapse prevention: Evidence supports redosing at 6-month intervals to maintain efficacy 3
• The protective effect appears to wane between 6-12 months after the last infusion 3
• Maintenance therapy particularly important for patients with:
  • History of relapse
  • Persistent antibody positivity
  • Incomplete response to acute therapy

Timing Considerations

Early initiation (≤3 months from symptom onset) associated with better long-term outcomes compared to delayed treatment (>3 months) 2

Monitoring Requirements

Pre-Treatment Screening

• Hepatitis B serology (HBsAg, anti-HBc, anti-HBs) - mandatory to prevent reactivation
• Hepatitis C screening
• HIV testing (in appropriate populations)
• Baseline immunoglobulin levels (IgG, IgM, IgA)
• Complete blood count with differential
• Pregnancy test in women of childbearing potential

Infusion Monitoring

• Premedication: Acetaminophen, antihistamine (diphenhydramine), and often corticosteroids to reduce infusion reactions
• Vital signs: Monitor during and for 1-2 hours post-infusion
• Infusion reactions occur in approximately 15.7% of patients, typically mild 4

Post-Treatment Monitoring

Short-term (first 6 months):

• CD19/CD20 B-cell counts at 3 and 6 months to confirm B-cell depletion
• Clinical assessment using validated scales (mRS, CASE score) at discharge, 3 months, 6 months
• Immunoglobulin levels every 3 months - watch for hypogammaglobulinemia

Long-term (ongoing):

• Clinical monitoring every 6 months for relapse symptoms
• Immunoglobulin levels every 6 months
• Infection surveillance: Pneumonia risk approximately 6%, serious sepsis 1.1% 4
• Consider IVIG replacement if IgG falls below 400-500 mg/dL with recurrent infections

Efficacy Monitoring

• Primary outcome: Modified Rankin Scale (mRS) improvement - expect mean decrease of 2.67 points 4
• Good functional outcome (mRS ≤2) achieved in 72.2% of patients 4
• Relapse rate: Only 14.2% with rituximab versus higher rates with conventional therapy 4
• Response timeline: Most improvement occurs within first 6 months, with continued gains up to 12-18 months 2, 5

Safety Profile and Common Pitfalls

Acceptable Toxicity

• Infusion reactions: 15.7% (usually mild, manageable with premedication) 4
• Infections: Pneumonia 6%, severe sepsis 1.1% 4
• No serious adverse events reported in most AE cohorts when properly monitored 2, 5

Critical Warnings

• Hepatitis B reactivation: Can be fatal - always screen before treatment
• Progressive multifocal leukoencephalopathy (PML): Rare but serious - maintain high index of suspicion for new neurological symptoms
• Hypogammaglobulinemia: Monitor and replace immunoglobulins if needed
• Live vaccines: Contraindicated during and for 12 months after rituximab

Common Pitfalls to Avoid

1. Waiting too long: Don't delay beyond 4 weeks of failed first-line therapy
2. Inadequate premedication: Always use acetaminophen and antihistamines
3. Missing hepatitis screening: This is non-negotiable
4. Stopping too early: Complete the full course even if early improvement occurs
5. No maintenance plan: Consider 6-month redosing for relapse prevention, especially in NMDAR encephalitis 3

Evidence Quality Note

The guideline recommendations 1 represent expert consensus from the Autoimmune Encephalitis Alliance Clinicians Network (2021), based on survey of 68 international experts and literature review. Supporting research demonstrates consistent benefit across multiple cohorts 2, 3, 5, 4, though randomized controlled trials are lacking. The evidence is strongest for NMDAR encephalitis and other neuronal surface antibody syndromes.